Henri Atlan

Title: Henri Atlan: Innovator in HIV Treatment

Introduction

Henri Atlan is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of immunology, particularly in the treatment of HIV infection. His innovative approach focuses on the use of inactivated CD8+ T-cells, which has the potential to improve the lives of immunodeficient HIV-infected patients.

Latest Patents

Henri Atlan holds a patent for a method involving inactivated CD8+ T-cells for the treatment of HIV infection. This patent describes a method for preparing a T cell vaccine aimed at immunodeficient HIV-infected patients. The process includes the enrichment of autologous CD4-reactive CD8 T cells. Additionally, the patent outlines a protocol for implementing T cell vaccination in these patients, as well as a treatment method based on the developed T cell vaccine. The patent also provides kits for preparing the T cell vaccine and for implementing the vaccination protocol.

Career Highlights

Throughout his career, Henri Atlan has worked with prominent organizations such as Yeda Research and Development Company and Hadasit Medical Research Services and Development. His work in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Henri Atlan has collaborated with notable colleagues, including Rivka Abulafia-Lapid and Irun R Cohen. These partnerships have further enriched his research and development efforts in the field of HIV treatment.

Conclusion

Henri Atlan's innovative work in the treatment of HIV through the use of inactivated CD8+ T-cells showcases his dedication to improving patient outcomes. His contributions to immunology and collaboration with esteemed colleagues highlight the importance of teamwork in advancing medical research.